Cargando…
Mitral valve repair with a device for artificial chordal implantation at 2 years
OBJECTIVES: This study examines the early and midterm safety, efficacy, and durability of mitral valve repair for primary mitral regurgitation (MR) using the ChordArt device (CoreMedic) for chordal replacement. METHODS: Five patients with symptomatic severe primary degenerative MR due to isolated ce...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390769/ https://www.ncbi.nlm.nih.gov/pubmed/36004154 http://dx.doi.org/10.1016/j.xjon.2021.08.041 |
_version_ | 1784770727120994304 |
---|---|
author | Weber, Alberto Taramasso, Maurizio Podkopajev, Andrej Janusauskas, Vilius Zakarkaite, Diana Vogel, Rolf Carrel, Thierry |
author_facet | Weber, Alberto Taramasso, Maurizio Podkopajev, Andrej Janusauskas, Vilius Zakarkaite, Diana Vogel, Rolf Carrel, Thierry |
author_sort | Weber, Alberto |
collection | PubMed |
description | OBJECTIVES: This study examines the early and midterm safety, efficacy, and durability of mitral valve repair for primary mitral regurgitation (MR) using the ChordArt device (CoreMedic) for chordal replacement. METHODS: Five patients with symptomatic severe primary degenerative MR due to isolated central posterior leaflet prolapse/flail were treated with the ChordArt device in a transseptal surgical approach and followed prospectively with periodical clinical and echocardiographic assessments for 2 years. RESULTS: Reduction of MR immediately after the implantation of artificial chords was achieved in all patients showing no or trace MR (<1+/4+). In all patients, MR <1+ was maintained during 24 months of follow-up. No dehiscence, detachment, or dislocation of the implanted ChordArt devices was observed. Transthoracic echocardiography showed that left ventricle end diastolic diameter significantly decreased during the whole follow-up period in comparison to baseline condition, especially at discharge and 1-month follow-up. Left ventricle end systolic diameter also significantly decreased during the whole follow-up period in comparison to baseline condition. Left atrial volume significantly decreased during the follow-up period in comparison to discharge. No major adverse events, as defined per protocol, were observed during the intervention or during the follow-up period. CONCLUSIONS: The ChordArt device allows successful treatment of primary degenerative MR due to posterior mitral leaflet prolapse or flail, with a good safety profile and promising immediate clinical and echocardiographic benefits that are confirmed up to 24 months. |
format | Online Article Text |
id | pubmed-9390769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93907692022-08-23 Mitral valve repair with a device for artificial chordal implantation at 2 years Weber, Alberto Taramasso, Maurizio Podkopajev, Andrej Janusauskas, Vilius Zakarkaite, Diana Vogel, Rolf Carrel, Thierry JTCVS Open Adult: Mitral Valve: Evolving Technology OBJECTIVES: This study examines the early and midterm safety, efficacy, and durability of mitral valve repair for primary mitral regurgitation (MR) using the ChordArt device (CoreMedic) for chordal replacement. METHODS: Five patients with symptomatic severe primary degenerative MR due to isolated central posterior leaflet prolapse/flail were treated with the ChordArt device in a transseptal surgical approach and followed prospectively with periodical clinical and echocardiographic assessments for 2 years. RESULTS: Reduction of MR immediately after the implantation of artificial chords was achieved in all patients showing no or trace MR (<1+/4+). In all patients, MR <1+ was maintained during 24 months of follow-up. No dehiscence, detachment, or dislocation of the implanted ChordArt devices was observed. Transthoracic echocardiography showed that left ventricle end diastolic diameter significantly decreased during the whole follow-up period in comparison to baseline condition, especially at discharge and 1-month follow-up. Left ventricle end systolic diameter also significantly decreased during the whole follow-up period in comparison to baseline condition. Left atrial volume significantly decreased during the follow-up period in comparison to discharge. No major adverse events, as defined per protocol, were observed during the intervention or during the follow-up period. CONCLUSIONS: The ChordArt device allows successful treatment of primary degenerative MR due to posterior mitral leaflet prolapse or flail, with a good safety profile and promising immediate clinical and echocardiographic benefits that are confirmed up to 24 months. Elsevier 2021-10-29 /pmc/articles/PMC9390769/ /pubmed/36004154 http://dx.doi.org/10.1016/j.xjon.2021.08.041 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Adult: Mitral Valve: Evolving Technology Weber, Alberto Taramasso, Maurizio Podkopajev, Andrej Janusauskas, Vilius Zakarkaite, Diana Vogel, Rolf Carrel, Thierry Mitral valve repair with a device for artificial chordal implantation at 2 years |
title | Mitral valve repair with a device for artificial chordal implantation at 2 years |
title_full | Mitral valve repair with a device for artificial chordal implantation at 2 years |
title_fullStr | Mitral valve repair with a device for artificial chordal implantation at 2 years |
title_full_unstemmed | Mitral valve repair with a device for artificial chordal implantation at 2 years |
title_short | Mitral valve repair with a device for artificial chordal implantation at 2 years |
title_sort | mitral valve repair with a device for artificial chordal implantation at 2 years |
topic | Adult: Mitral Valve: Evolving Technology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390769/ https://www.ncbi.nlm.nih.gov/pubmed/36004154 http://dx.doi.org/10.1016/j.xjon.2021.08.041 |
work_keys_str_mv | AT weberalberto mitralvalverepairwithadeviceforartificialchordalimplantationat2years AT taramassomaurizio mitralvalverepairwithadeviceforartificialchordalimplantationat2years AT podkopajevandrej mitralvalverepairwithadeviceforartificialchordalimplantationat2years AT janusauskasvilius mitralvalverepairwithadeviceforartificialchordalimplantationat2years AT zakarkaitediana mitralvalverepairwithadeviceforartificialchordalimplantationat2years AT vogelrolf mitralvalverepairwithadeviceforartificialchordalimplantationat2years AT carrelthierry mitralvalverepairwithadeviceforartificialchordalimplantationat2years |